Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on September 21, 2017, covering events that occurred on September 15, 2017. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and does not contain financial performance data.
Material Changes
On September 15, 2017, the Board of Directors approved stock option awards under the Company's 2014 Stock Incentive Plan as part of its annual compensation review. The recipients were:
- Myron Holubiak, President and Chief Executive Officer
- Leonard Mazur, Executive Chairman
Each executive was granted options to purchase 40,000 shares of common stock at an exercise price of $3.45 per share, which was the closing price on the day prior to the grant.
Terms and Vesting Schedule
The stock options have the following terms:
- Vesting: One-third vests on September 13, 2018. The remaining options vest in equal monthly installments over the subsequent two years, contingent upon continuous service.
- Expiration: September 13, 2027.
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific compensation details noted above.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2014 Stock Incentive Plan to assess dilution impact.
- Confirm the current market price of Citius Pharmaceuticals stock relative to the $3.45 exercise price.
- Review the Company's cash position to determine if the vesting schedule aligns with projected liquidity needs.
- Check for any subsequent filings regarding changes to the 2014 Stock Incentive Plan.